Full-Time
BlueRock Therapeutics
201-500 employees
Develops advanced cellular therapies for diseases
No salary listed
Mid, Senior
New York, NY, USA
This is a hybrid position, indicating that the candidate will be required to work in-office some days.
- Ph.D OR M.S. in a relevant field and a minimum of 2 years OR BS and a minimum of 4 years of relevant professional experience in bioinformatics, computational biology, biomedical engineering, or a related discipline
- Experience building NGS bioinformatics pipelines
- Comfortable working in Linux
- Proven ability to program efficiently in Python, R, and Bash
- Comfortable with git version control
- Knowledge of molecular and cellular biology
- Proven ability to work independently on assigned projects simultaneously for cross-functional teams across multiple locations
- Effective communication, organizational, and interpersonal skills
- Motivation to build a culture of innovation with aspirations to develop products that will change the lives of people with serious diseases, their families, and society
- Contribute to the development of internal scientific software
- Build and analyze bioinformatics NGS pipelines, particularly around genomics and transcriptomics
- Assist in building and deployment of internal scientific software
- Assist in the tech and knowledge transfer of bioinformatics pipelines and software across teams
- Provide analysis from computational pipelines and effectively communicate them cross-functionally
BlueRock Therapeutics develops advanced cellular therapies using a unique cell gene platform that directs cellular differentiation and genetically engineers cells. This technology allows them to create new types of medicines aimed at treating diseases in neurology, cardiology, and immunology. Their products work by transforming cells to target complex medical conditions such as neurodegenerative diseases, heart failure, and immune disorders. Unlike many competitors, BlueRock focuses specifically on these challenging areas and operates through a business model that emphasizes research and development, as well as strategic partnerships with healthcare providers and pharmaceutical companies. Their goal is to advance their cell gene platform and develop a pipeline of therapies that can be commercialized after receiving regulatory approval.
Company Size
201-500
Company Stage
Acquired
Total Funding
$1.2B
Headquarters
Cambridge, Massachusetts
Founded
2016
Simplify's Take
What believers are saying
- FDA RMAT designation for bemdaneprocel accelerates market entry for Parkinson's therapy.
- Successful Phase I trial of bemdaneprocel boosts investor confidence and funding potential.
- Collaboration with bit.bio enhances discovery and development of new cell therapies.
What critics are saying
- Competition from established firms like Johnson & Johnson may overshadow BlueRock's innovations.
- Reliance on strategic partnerships poses risks if partners shift focus or resources.
- Regulatory hurdles could delay product launches, impacting revenue and market position.
What makes BlueRock Therapeutics unique
- BlueRock uses iPSC technology to create novel cellular therapies for complex diseases.
- Their strategic partnerships enhance R&D capabilities and expand therapeutic applications.
- Focus on neurology, cardiology, and immunology addresses challenging medical conditions.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 3%OpCT-001 is the first iPSC therapy candidate licensed from the strategic research and development alliance that FUJIFILM Cellular Dynamics, Opsis Therapeutics, and BlueRock Therapeutics entered in 2021 to discover and develop off-the-shelf iPSC-derived cell therapies for ocular diseases.
Since May 2021, BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics have had an R&D alliance to develop allogeneic iPSC-derived cell therapies for ocular diseases.
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to bemdaneprocel, a cell therapy BlueRock Therapeutics, a subsidiary of Bayer, is developing to treat Parkinson's disease.
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year.At one-year, exploratory clinical endpoints improved overall, with participants in the high dose cohort showing greater improvement.One year assessment of all participants demonstrated feasibility of transplantation, cell survival, and engraftment.Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.BERLIN and CAMBRIDGE, Mass., Aug. 28, 2023 /PRNewswire/ -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of the positive data from the Phase I clinical trial for bemdaneprocel (BRT-DA01), a stem cell derived investigational therapy for treating Parkinson's disease. The data were presented at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.The study met the primary objective of demonstrating safety and tolerability in all 12 participants in the study's low and high dose cohorts, with no serious adverse events (SAEs) reported related to bemdaneprocel through one year. There were two SAEs reported that were unrelated to bemdaneprocel, one seizure attributed to the surgical procedure and one COVID case. Both resolved without sequelae. In addition, 18F-DOPA PET imaging scans demonstrated evidence of cell survival and engraftment in both low and high dose cohorts
BlueRock and bit.bio link to develop regulatory T cell-based therapies.